MMG Introduces Enhanced Education Platform for Clinical Trials
MMG announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations
MMG, a global health communications company specializing in clinical trial patient recruitment and retention, announced an exclusive strategic partnership with online healthcare communications company MedRespond to introduce Custom Conversations, its new technological advancement in clinical trial patient education.
Custom Conversations uses video, natural language query capabilities, and the Internet to allow people exploring clinical trial options to have a more customized online learning interaction. An advanced synthetic interview technology developed by Carnegie Mellon University, allows people to also can ask questions in their own words, and then receive pre-recorded video responses which have been pre-approved by the study’s institutional review board or ethics committee.
According to MMG, pilot programs have shown clear boosts in enrollment rates compared to trials for which patients received only traditional study educational materials.
The Custom Conversations platform can be also be leveraged throughout the study education continuum – from first learning about a study, to pre-qualification and screening, and for the duration of the study, which can help to fortify retention. Sponsors receive insight into the anonymous activity data to get a view into patients’ and caregivers’ communication needs and mindsets, which can be used to refine recruitment and retention strategies and messaging.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025